Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
COLL
BuyUnloved QualityAPPROVECollegium Pharmaceutical, Inc. · Healthcare · United States · $786M · Avg Vol: $20M/d
Collegium Pharmaceutical generates strong cash flow from its abuse-deterrent pain portfolio and an acquired attention-deficit product, and it has used that cash to repay debt and repurchase shares, supporting a good quality score (Q70). The trivial insider selling is routine. Nothing adverse is known on accounting, solvency or governance.
COMPANY DESCRIPTION
Collegium Pharmaceutical, Inc. is a specialty pharmaceutical company focused on developing and commercializing tamper-deterrent, abuse-deterrent formulations of pain medications. Leveraging its proprietary DETERx® technology, the company addresses the critical public health need for safer opioid analgesics. Collegium holds a niche market position by combining pain management with abuse-deterrent technology.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 463.9M | 566.8M | 631.4M | 780.6M | 18.9% | 808.2M | 836.8M | 828.1M | 3.0% |
| EPS | -0.74 | 1.43 | 2.14 | 1.98 | 17.7% | 1.27 | 1.99 | 1.81 | -4.5% |
| Shares | 33.8M | 31.9M | 31.4M | 31.7M | -6.3% | 31.0M | — | — | — |
| Debt | 709.2M | 674.3M | 859.3M | 814.9M | 4.7% | 1.2B | — | — | — |
| Equity | 194.8M | 195.4M | 228.8M | 301.7M | 15.7% | — | — | — | — |
| Op CF | 124.2M | 274.7M | 205.0M | 329.3M | 38.4% | 329.9M | — | — | — |
| Inv CF | -573.7M | -70.8M | -287.8M | -63.5M | — | — | — | — | — |
| Fin CF | 436.7M | -140.2M | -60.6M | -110.2M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of COLL are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| COLL | Collegium Pharmaceutical, Inc.(you) | $786M | 72 | Buy |
| PAHC | Phibro Animal Health Corporation | $1.5B | 74 | Buy |
| ETON | Eton Pharmaceuticals, Inc. | $1.7B | 72 | Buy |
| PCRX | Pacira BioSciences, Inc. | $1.0B | 85 | Strong Buy |
| EOLS | Evolus, Inc. | $587M | 55 | Hold |
| XERS | Xeris Biopharma Holdings, Inc. | $1.5B | 60 | Hold |
| AMPH | Amphastar Pharmaceuticals, Inc. | $936M | 95 | Strong Buy |
| EBS | Emergent BioSolutions Inc. | $303M | 64 | Hold |
| PBH | Prestige Consumer Healthcare Inc. | $2.5B | 67 | Buy |
| ANIK | Anika Therapeutics, Inc. | $282M | 64 | Hold |
Peer medians: ROE -30.8% · P/E 27.1x · Gross margin 58.1%